The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Immune Microenvironment in Glioblastoma Subtypes
Open accessAbstract
Glioblastomas (GBMs) are the most common and aggressive primary brain tumors. Due to their malignant growth and invasion into the brain parenchyma coupled with resistance to therapy, GBMs are among the deadliest of all cancers. GBMs are highly heterogeneous at both the molecular and histological levels. Hallmark histological structures include pseudopalisading necrosis and microvascular proliferation. In addition to high levels of intratumoral heterogeneity, GBMs also exhibit high levels of inter-tumoral heterogeneity. The major non-neoplastic cell population in the GBM microenvironment includes cells of the innate immune system called tumor-associated macrophages (TAMs). Correlative data from the literature suggest that molecularly distinct GBM subtypes exhibit differences in their microenvironment. Data from mouse models of GBM suggest that genetic driver mutations can create unique microenvironments. Here, we review the origin, features, and functions of TAMs in distinct GBM subtypes. We also discuss their interactions with other immune cell constituents and discuss prospects of therapeutically targeting TAMs to increase the efficacy of T-cell functions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · cited 1×
“Subsequently, a range of differentiation has been proposed, with the M1 and M2 phenotypes being at the ends of the spectrum (53).”
BackgroundComprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190 · cited 1×
“Once homing to inflamed tissues, these cells gradually downregulate their CCR2 while concomitantly upregulating CX3CR1 as they differentiate into macrophages (41).”
BackgroundFate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M. F., Conway, S. J., Ng, L. G., Stanley, E. R., et al. (2010) · Science · doi:10.1126/science.1194637 · Cited by 5,175 · cited 1×
“5, these progenitors migrate from the yolk sac into the primitive brain, where they serve as cells of origin for microglia (33).”
Background
Cited by
Mechanisms of immunotherapy resistance: lessons from glioblastoma
Jackson, C. M., Choi, J., & Lim, M. (2019) · Nature Immunology · doi:10.1038/s41590-019-0433-y · Cited by 751
Proteogenomic and metabolomic characterization of human glioblastoma
Wang, L.-B., Karpova, A., Gritsenko, M. A., Kyle, J. E., Cao, S., Li, Y., Rykunov, D., Colaprico, A., Rothstein, J. H., Hong, R., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.006 · Cited by 661
Ravi, V. M., Neidert, N., Will, P., Joseph, K., Maier, J. P., Kückelhaus, J., Vollmer, L., Goeldner, J. M., Behringer, S. P., Scherer, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28523-1 · Cited by 343
Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications
Cheng, J., Meng, J., Zhu, L., & Peng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01189-3 · Cited by 319
Tumour treating fields therapy for glioblastoma: current advances and future directions
Rominiyi, O., Vanderlinden, A., Clenton, S. J., Bridgewater, C., Al-Tamimi, Y., & Collis, S. J. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01136-5 · Cited by 315
A review of glioblastoma immunotherapy
Medikonda, R., Dunn, G., Rahman, M., Fecci, P., & Lim, M. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03448-1 · Cited by 295
Chen, C., Jing, W., Chen, Y., Wang, G., Abdalla, M., Gao, L., Han, M., Shi, C., Li, A., Sun, P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1128 · Cited by 291
The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma
Goenka, A., Tiek, D., Song, X., Huang, T., Hu, B., & Cheng, S.-Y. (2021) · Cells · doi:10.3390/cells10030484 · Cited by 169
Glioblastoma Microenvironment and Cellular Interactions
Crivii, C.-B., Boșca, A. B., Melincovici, C. S., Constantin, A.-M., Mărginean, M., Dronca, E., Suflețel, R., Gonciar, D., Bungărdean, M., & Șovrea, A. (2022) · Cancers · doi:10.3390/cancers14041092 · Cited by 81
Immunotherapy in Glioblastoma: A Clinical Perspective
Desbaillets, N., & Hottinger, A. F. (2021) · Cancers · doi:10.3390/cancers13153721 · Cited by 31
Sun, Y., Zhang, Z., Zhang, C., Zhang, N., Wang, P., Chu, Y., Chard Dunmall, L. S., Lemoine, N. R., & Wang, Y. (2022) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2022.05.008 · Cited by 30
Multiple Faces of the Glioblastoma Microenvironment
Șovrea, A. S., Boșca, B., Melincovici, C. S., Constantin, A.-M., Crintea, A., Mărginean, M., Dronca, E., Jianu, M. E., Suflețel, R., Gonciar, D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020595 · Cited by 26
Immunotherapeutic advances in glioma management: The rise of vaccine‐based approaches
Andrew Awuah, W., Shah, M. H., Tan, J. K., Ranganathan, S., Sanker, V., Darko, K., Tenkorang, P. O., Adageba, B. B., Ahluwalia, A., Shet, V., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70013 · Cited by 14
Chen, J., Liu, Z., Fang, H., Su, Q., Fan, Y., Song, L., & He, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05151-5 · Cited by 10
Metadata
- Authors
- Chen, Z., & Hambardzumyan, D.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-05-08
- Volume
- 9
- Pages
- 1004-1004
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2799441834
- Cited by
- 432
- References
- 78
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.